Your session is about to expire
← Back to Search
Radiation
99mTc-MAA Injection for Cancer (MAApping Trial)
Phase 4
Waitlist Available
Led By Douglas Murrey, MD
Research Sponsored by Sirtex Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18-24 hours
Awards & highlights
MAApping Trial Summary
This trial tests a new radiation dose for liver cancer treatment to reduce damage to other parts of the body.
Eligible Conditions
- Cancer
- Hepatocellular Carcinoma
- Liver Cancer
MAApping Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18-24 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18-24 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Effective dose (Gy) for the whole body
Mean absorbed dose (Gy) for critical non-liver organs
Mean absorbed dose (Gy) for the whole body
+2 moreMAApping Trial Design
1Treatment groups
Experimental Treatment
Group I: 99mTc-MAA InjectionExperimental Treatment1 Intervention
Patients enrolled in the study will have 3 imaging scans taken after 99mTc-MAA Injection with the final scan occurring 18-24 hours after injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
99mTc-Macro Albumin Aggregate
2023
Completed Phase 4
~10
Find a Location
Who is running the clinical trial?
Sirtex MedicalLead Sponsor
28 Previous Clinical Trials
4,265 Total Patients Enrolled
Bright Research PartnersIndustry Sponsor
13 Previous Clinical Trials
1,749 Total Patients Enrolled
Douglas Murrey, MDPrincipal InvestigatorInland Imaging
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger